Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes

Published:2016-02 Issue:2 Volume:22 Page:277-283
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Danylesko Ivetta,Sareli Rina,Bloom-Varda Nira,Yerushalmi Ronit,Shem-Tov Noga,Shimoni Avichai,Nagler Arnon

Funder

Teva LtD

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference30 articles.

1. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial;Suciu;Blood,2003

2. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML;Bornhauser;Blood,2007

3. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials;Koreth;JAMA,2009

4. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review;Oliansky;Biol Blood Marrow Transplant,2009

5. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia;Sierra;Blood,2002

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is split‐dose better than single‐dose? Results of Turkish Stem Cell Coordination Center ( TURKOK ) donors in the era of rising biosimilar G‐CSF;Journal of Clinical Apheresis;2022-06-11

2. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors;International Journal of Hematology;2022-04-09

3. Comparative study on the effects of filgrastim and pegfilgrastim in the treatment of fever and neutropenia in patients with leukemia in the west of Iran;Iranian Journal of Pediatric Hematology & Oncology;2022-03-30

4. Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology;Journal of Oncology Pharmacy Practice;2021-05-14

5. Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim;BioDrugs;2019-08-22